Ignite Creation Date:
2024-06-16 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06435013
Status:
COMPLETED
Last Update Posted:
2024-05-30
First Post:
2024-05-24
Brief Title:
Lenvatinib vs Bevacizumab Plus ICIs and HAIC in Unresectable HCC
Sponsor:
Sun Yat-sen University
Organization:
Sun Yat-sen University
Study Overview
Official Title:
Lenvatinib Versus Bevacizumab Combined With Immune Checkpoint Inhibitors and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma A Retrospective Multi-center and Propensity Score Matching Study
Status:
COMPLETED
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Previous studies had suggested hepatic arterial infusion chemotherapy HAIC combined with immune checkpoint inhibitors ICIs and anti-angiogenic drugs had promising anti-tumor activity in unresectable hepatocellular carcinoma HCC Two kinds of anti-angiogenic drugs tyrosine kinase inhibitors lenvatinib and anti-VEGF antibody bevacizumab were applied in first-line treatment of unresectable HCC However little is known about the difference of efficacy and safety between lenvatinib LenHAP or bevacizumab BevHAP combined with ICIs and HAIC in unresectable HCC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None